{"componentChunkName":"component---src-templates-chapter-level-1-chapter-level-1-tsx","path":"/topics/antiplatelet-treatment/supporting-evidence/","result":{"pageContext":{"chapter":{"id":"ec007ae2-2b14-50b1-a091-3875c81c5adb","slug":"supporting-evidence","fullItemName":"Supporting evidence","depth":1,"htmlHeader":"<!-- begin field e47b37be-b4ae-49be-9c07-35ddcc028b42 --><h1>Supporting evidence</h1><!-- end field e47b37be-b4ae-49be-9c07-35ddcc028b42 -->","summary":null,"htmlStringContent":"<!-- begin item 9630eb09-c0bd-4435-a32e-4c81abf372f9 --><!-- begin field 2ce10778-c516-4ad4-9c8f-a8f600a526f8 --><p>This CKS topic is largely based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Stable angina: management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2016a</a>], <em>Unstable angina and NSTEMI: early management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2013a</a>], <em>Clopidogrel and modifified-release dipyridamole for the prevention of occlusive vascular events</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2010a</a>], <em>Myocardial infarction: cardiac rehabilitation and prevention of further cardiovascular disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2013b</a>], the NICE evidence summary <em>Transient ischaemic attack: clopidogrel</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2013c</a>], the NICE technology appraisal <em>Ticagrelor for preventing atherothrombotic events after myocardial infarction</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2016b</a>], the Scottish Intercollegiate Guidelines Network (SIGN) guidelines <em>Risk estimation and the prevention of cardiovascular disease </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">SIGN, 2017</a>], <em>Antithrombotics: indications and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">SIGN, 2013</a>] and <em>Management of stable angina</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">SIGN, 2018</a>], the Royal College of Physicians (RCP) <em>National clinical guideline for stroke</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">RCP, 2016</a>], and the European Society of Cardiology (ECS)<em> 2016 European Guidelines on cardiovascular disease prevention in clinical practice</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ESC, 2016</a>], and <em>2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ESC, 2018a</a>]. The rationale for individual recommendations is discussed in the relevant basis for recommendation sections of this topic.</p><!-- end field 2ce10778-c516-4ad4-9c8f-a8f600a526f8 --><!-- end item 9630eb09-c0bd-4435-a32e-4c81abf372f9 -->","topic":{"id":"86dfa76b-bc1a-5d4b-bf7c-018d5d031947","topicId":"a68e1521-d84e-4abb-bb17-6186ba7a891a","topicName":"Antiplatelet treatment","slug":"antiplatelet-treatment","lastRevised":"Last revised in August 2020","chapters":[{"id":"af85e41e-4007-5daa-bc95-35aa03621ea0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"db8ef934-0123-530e-9f34-52d23ea99e56","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"ebaf9360-bb92-51bc-8aba-ac3293fa1416","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b34f13e6-85f8-5c85-b2f7-5678c0779a07","slug":"changes","fullItemName":"Changes"},{"id":"9532ea0d-f7f7-5a08-9076-dedbf78ca97d","slug":"update","fullItemName":"Update"}]},{"id":"0370616e-85d0-5654-b5ad-ea9980ad8eaa","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"24bebba9-1157-505c-834d-bf255dd856a9","slug":"goals","fullItemName":"Goals"},{"id":"b1ab86f3-b045-5a24-b8ea-506ae6fa94c8","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cb61b0c8-a7f6-5e31-af33-9c4ade31a493","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"19dcf0a2-d60c-5fe4-94b7-d902d7cc17f8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"758947ec-f9bc-59c9-a07f-663f738f5428","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8c16356c-f5cf-54fc-99e8-ccc08af83ec7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"30e0cacd-1816-520e-8f4a-aba760ce71f5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"9e23a119-ae6d-5e11-9691-ed23c4016c39","slug":"definition","fullItemName":"Definition"},{"id":"2ef5b7fd-3211-5769-8a72-083d9f8c40c8","slug":"mechanism-of-action","fullItemName":"Mechanism of action"},{"id":"ef9f4561-2787-59c9-974b-b656929c553c","slug":"indications","fullItemName":"Indications"},{"id":"7692771a-8763-57f6-b4fe-d4711f820cfb","slug":"complications","fullItemName":"Complications"}]},{"id":"d31d1a85-d8c2-5598-b7e0-e8b2da36e45c","fullItemName":"Management","slug":"management","subChapters":[{"id":"81844a0f-b280-563a-b66c-4a5dba6e1e9c","slug":"primary-prevention-of-cvd","fullItemName":"Scenario: Primary prevention of CVD"},{"id":"c2fb4ffa-788d-5d77-a694-3e30c3008d35","slug":"secondary-prevention-of-cvd","fullItemName":"Scenario: Secondary prevention of CVD"}]},{"id":"85828cd6-6943-58a7-9657-71760be76497","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d408bf47-147e-5914-ab35-c4142ec2a33e","slug":"low-dose-aspirin","fullItemName":"Low dose aspirin"},{"id":"4098d4bf-7db2-5e79-bdec-17a2bbfaca6a","slug":"clopidogrel","fullItemName":"Clopidogrel"},{"id":"d5d8e5ca-9f57-5ac9-955b-614b85700f3e","slug":"dipyridamole","fullItemName":"Dipyridamole"},{"id":"52159350-4f8e-536b-99c4-a75908d6233a","slug":"prasugrel","fullItemName":"Prasugrel"},{"id":"92100407-8f08-53c0-8df1-1e802f4dcbe9","slug":"ticagrelor","fullItemName":"Ticagrelor"}]},{"id":"ec007ae2-2b14-50b1-a091-3875c81c5adb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f54cfffb-be9e-5523-a47f-c1100845c9c4","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4ce7f1c7-df35-54c7-9f8b-b1aefe5762f1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f4d603b9-b19a-53ac-8058-8c414be0a10b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"69fb4d5c-2946-5ef6-8c7f-b5f81dd52f9c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d1e16069-862f-500a-9f58-e84cb201da64","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"fab694fa-9176-5402-b7b5-729a22dd611f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3852e22b-c968-5afe-81be-ac1efce390da","fullItemName":"References","slug":"references","subChapters":[]}]},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}